No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
J.P. Morgan's Top Healthcare Stocks for 2025
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Guggenheim Reiterates Buy on Blueprint Medicinesto Buy
Reported Saturday, Blueprint Medicines Showcases AYVAKIT'S Survival Benefits And Disease-Modifying Effects In Advanced Systemic Mastocytosis At ASH 2024
Blueprint Medicines: A Promising Investment With Innovative Treatments and Strong Financial Position
Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue?